Mice receiving CISE@Gel exhibited a prominent decline in tumor growth, which was far more effective than CS@Gel and CIS@Gel, which may be attributed to the superimposed effects of IDO1 silencing and CD62E‐mediated tumor targeting. The gene discussed is SELE; the disease is neoplasm.